Alpha interferon improves survival in patients with metastatic renal carcinoma - Updated results of an MRC randomised controlled trial.

被引：0
|
作者：
Oliver, RTD [1 ]
机构：
[1] MRC, Clin Trials Unit, Canc Div, Cambridge CB2 2BW, England
来源：
BRITISH JOURNAL OF CANCER | 1999年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P161
引用
收藏
页码：69 / 69
页数：1
相关论文
共 50 条
  • [21] Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial.
    Lee, Chung-Han
    Fitzgerald, Kelly N.
    Voss, Martin H.
    Carlo, Maria Isabel
    Knezevic, Andrea
    Peralta, Laura
    Chen, Ying-Bei
    Zucker, Mark
    Lefkowitz, Robert A.
    Reznik, Eduard
    Shah, Neil J.
    Owens, Colette Ngozi
    McHugh, Deaglan Joseph
    Aggen, David H.
    Laccetti, Andrew Leonard
    Kotecha, Ritesh R.
    Feldman, Darren R.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Camrelizumab plus famitinib for advanced renal cell carcinoma or unresectable urothelial carcinoma: Updated results from a phase II trial.
    Qu, Yuan-Yuan
    Zou, Qing
    Guo, Hongqian
    Xing, Nianzeng
    Sun, Zhongquan
    Han, Weiqing
    Luo, Hong
    Xia, Shujie
    Zhang, Xuepei
    He, Chaohong
    Zhang, Hailiang
    Cai, Jinling
    Zhang, Xiao
    Wang, Quanren
    Ye, Dingwei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] Resection of nodal disease in patients with metastatic conventional renal cell carcinoma improves survival
    Brassell, S
    Sanchez-Ortiz, RF
    Matin, SF
    Swanson, DA
    Wood, CG
    JOURNAL OF UROLOGY, 2006, 175 (04): : 241 - 242
  • [24] The Impact of Combination Therapy of Sunitinib with Interferon-Alpha on Survival of Patients with Loco Regional and Metastatic Clear Renal Cell Carcinoma
    Aznab, Mozaffar
    Rezaei, Mansour
    INTERNATIONAL JOURNAL OF CANCER MANAGEMENT, 2018, 11 (10)
  • [25] The MRC randomised-controlled trial of interferon-α, interleukin-2 and 5-fluorouracil vs interferon-α alone in patients with advanced renal cell carcinoma (RE04):: Rationale and progress
    Larkin, JMG
    Gore, ME
    CLINICAL ONCOLOGY, 2005, 17 (05) : 319 - 321
  • [26] Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan
    Masatoshi Eto
    Yoshiaki Kawano
    Yoshihiko Hirao
    Koji Mita
    Yoichi Arai
    Taiji Tsukamoto
    Katsuyoshi Hashine
    Akio Matsubara
    Tomoaki Fujioka
    Go Kimura
    Nobuo Shinohara
    Katsunori Tatsugami
    Shiro Hinotsu
    Seiji Naito
    BMC Cancer, 15
  • [27] Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan
    Eto, Masatoshi
    Kawano, Yoshiaki
    Hirao, Yoshihiko
    Mita, Koji
    Arai, Yoichi
    Tsukamoto, Taiji
    Hashine, Katsuyoshi
    Matsubara, Akio
    Fujioka, Tomoaki
    Kimura, Go
    Shinohara, Nobuo
    Tatsugami, Katsunori
    Hinotsu, Shiro
    Naito, Seiji
    BMC CANCER, 2015, 15
  • [28] Erratum to: Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma
    Masashi Niwakawa
    Katsuyoshi Hashine
    Raizo Yamaguchi
    Hirofumi Fujii
    Yasuo Hamamoto
    Koichi Fukino
    Takahiko Tanigawa
    Yoshiteru Sumiyoshi
    Investigational New Drugs, 2012, 30 (3) : 1274 - 1275
  • [29] ON THE DEVELOPMENT OF THE MEDICAL-RESEARCH-COUNCIL TRIAL OF ALPHA-INTERFERON IN METASTATIC RENAL-CARCINOMA
    FAYERS, PM
    COOK, PA
    MACHIN, D
    DONALDSON, N
    WHITEHEAD, J
    RITCHIE, A
    OLIVER, RTD
    YUEN, P
    STATISTICS IN MEDICINE, 1994, 13 (21) : 2249 - 2260
  • [30] Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis - Results of a randomized controlled trial
    Negrier, Sylvie
    Perol, David
    Ravaud, Alain
    Chevreau, Christine
    Bay, Jacques-Olivier
    Delva, Remy
    Sevin, Emmanuel
    Caty, Armelle
    Escudier, Bernard
    CANCER, 2007, 110 (11) : 2468 - 2477
12345